
Stop Guessing Your Heart Risk. Do This Instead | Dr John Osborne
Dr. John Osborne, a triple board-certified preventive cardiologist, reveals that cardiovascular disease (CVD) causes about 40% of all deaths in the US – more than the next seven causes combined, including cancer. Globally, 20 million people die from it each year. The root cause is arterial plaque, which builds up silently over decades. Alarmingly, half of men and two-thirds of women have no warning symptoms before their first heart attack or stroke; the first symptom is often sudden death.
Why Traditional Risk Assessments Fall Short- Risk factors like cholesterol, blood pressure, smoking, and diabetes are important but do not tell you whether you actually have plaque.
- The PREVENT calculator (from AHA/ACC) is publicly available but accurate only for populations, not individuals.
- Family history, especially a sibling with CVD, is a major genetic red flag often overlooked.
- Soft (lipid-rich) plaque: dangerous, prone to rupture, causing heart attacks or strokes.
- Hard (calcified) plaque: more stable, like an extinct volcano. A calcium score only detects this type, missing 10–50% of people who have only soft plaque.
Cardiac CT angiography (CCTA) combined with AI enables:
- Visualization of all plaque types (soft, hard, mixed)
- Quantitative plaque analysis – precise volume in cubic millimeters
- Tracking plaque over time – can we see if plaque is improving, worsening, or stable?
AI analyzes over 2,000 shades of gray (vs. 50 visible to the human eye), providing a “Superman-like” view of the vessels.
Treatment and Plaque Reversal- Once plaque embeds in the vessel wall, it doesn't simply disappear. The goal is to convert active soft plaque into stable calcified plaque.
- This is achieved through lifestyle changes, diet, exercise, and medications (e.g., statins, GLP-1 agonists, SGLT2 inhibitors).
- Now, for the first time, we can directly measure whether therapy is working on the plaque itself – not just on blood markers.
- Start screening at age 40 (earlier if high risk), analogous to colon cancer screening.
- 99% of people have detectable plaque – but the amount varies hugely.
- Follow-up intervals:
- No plaque: every 3–5 years
- Stage 1 (mild): 3 years
- Stage 2 (moderate): 2 years
- Stage 3 (severe): 1 year
Dr. Osborne highlights upcoming results for Pelacarsen, a drug targeting Lp(a) – a genetic, highly dangerous form of cholesterol affecting 20% of people. Future innovations include gene editing and epigenetic editing to permanently shut off cholesterol production.
Bottom Line“Stop guessing your heart risk – get scanned.” With CCTA and AI, we can detect CVD early, personalize treatment, and ultimately eradicate heart disease. Dr. Osborne’s mission: to put himself out of business.
👉 Learn more: cleerlycardio.com or YouTube channel “Clear Cardio”.






